Tyrosine kinase inhibitors (TKI) and immune-checkpoint inhibitors (ICI) are treatment options for metastatic renal cell cancer (mRCC). However, the treatment options after nivolumab are unclear.
The medical records of 57 consecutive Japanese mRCC patients who underwent treatment with axitinib were reviewed.